R. Ammerlaan

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

W. M. Smit, M. Kersten, P. Sonneveld, 2013, Annals of Hematology.

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

P. Sonneveld, M. Kooi, H. Lokhorst, 2008 .

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

M. Kersten, P. Sonneveld, B. van der Holt, 2012, Blood.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

P. Sonneveld, R. van der Griend, H. Lokhorst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

M. Kersten, P. Sonneveld, B. van der Holt, 2015, Haematologica.